Financial News

Financial Report: Merck

JANUVIA and KEYTRUDA sales drive growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck 1Q Revenues: $9.3 billion (+3%) 1Q Earnings: $1.1 billion (+18%) Comments: Pharmaceutical sales were $8.1 billion in the quarter, down 2%. JANUVIA / JANUMET sales were $1.4 billion, up 4%. ZETIA / VYTORIN sales were $889 million, up 4%. KEYTRUDA sales were $249 million in the quarter, which continues to launch with new indications in new markets. CUBICIN sales were up 57% to $292 million. 1Q15 reflects approximately two months of sales following the acquisition of Cubist Pharmaceu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters